Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam dose comparison with butorphanol for sedation during gastrointestinal endoscopy
ChiCTR2100042687Phase 4Recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of remimazolam and butorphanol (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Sedation success rate and Sedation induction time. Started Jan 2021; status: recruiting.
02
Drugs
remimazolambutorphanol
Beyond the preview
Go deeper on ChiCTR2100042687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042687.